IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Immatics US, Inc.
National Cancer Institute (NCI)
Bristol-Myers Squibb
Travera Inc
USWM, LLC (dba US WorldMeds)
National Institutes of Health Clinical Center (CC)
AstraZeneca
Sotio Biotech Inc.
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Dragonfly Therapeutics
Filamon LTD
Fondazione del Piemonte per l'Oncologia
Dana-Farber Cancer Institute
Hoffmann-La Roche
ViroMissile, Inc.
Dana-Farber Cancer Institute
Kaiser Permanente
Children's Oncology Group
Pfizer
Arvinas Inc.
Tizona Therapeutics, Inc
BioInvent International AB
Essen Biotech
Essen Biotech
Azienda Ospedaliero-Universitaria di Parma
Daiichi Sankyo
DualityBio Inc.
MacroGenics
xCures
Daiichi Sankyo
University of Nebraska
Natera, Inc.
Second Life Therapeutics
Ocellaris Pharma, Inc.
Fusion Pharmaceuticals Inc.
Innate Pharma
Novartis
M.D. Anderson Cancer Center
Mayo Clinic
Degron Therapeutics Co.
University Health Network, Toronto
Cancer Research UK
NeoTX Therapeutics Ltd.
University Health Network, Toronto
Cancer Research UK